4000-520-616
欢迎来到免疫在线!(蚂蚁淘生物旗下平台)  请登录 |  免费注册 |  询价篮
MedKoo(授权代理)
主营:主营:抗癌化学试剂和激酶抑制剂
咨询热线电话
4000-520-616
当前位置: 首页 > 产品中心 > peptide > MedKoo/PD089828featured/5mg/406476
商品详细MedKoo/PD089828featured/5mg/406476
MedKoo/PD089828featured/5mg/406476
MedKoo/PD089828featured/5mg/406476
商品编号: 406476
品牌: MedKoo
市场价: ¥5400.00
美元价: 3240.00
产地: 美国(厂家直采)
公司:
产品分类: 多肽合成
公司分类: peptide
联系Q Q: 3392242852
电话号码: 4000-520-616
电子邮箱: info@ebiomall.com
商品介绍

PD089828
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#:406476

CAS#:179343-17-0

Description:PD089828 is a potent FGFR inhibitor, which inhibits human full-length fibroblast growth factor (FGF) receptor-1 (FGFR-1), platelet-derived growth factor (PDGF) receptor beta subunit (PDGFR-beta), Src nonreceptor tyrosine kinase (c-Src) and epidermal growth factor (EGF) receptor (EGFR) tyrosine kinases with half-maximal inhibitory potencies (IC50 values) of 0.15 +/- 0.02 (n = 4), 0.18 +/- 0.04 (n = 3), 1.76 +/- 0.28 (n = 4) and 5.47 +/- 0.78 (n = 6) microM, respectively. The results highlight the biological characteristics of PD 089828 as a novel, broadly active protein tyrosine kinase inhibitor with long-lasting but reversible cellular effects. The potential therapeutic use of these broadly acting, nonselective inhibitors as antiproliferative and antimigratory agents could extend to such diseases as cancer, atherosclerosis and restenosis in which redundancies in growth-signaling pathways are known to exist.

Price and Availability

SizePriceShipping out timeQuantity
5mgUSD 2702 Weeks
10mgUSD 4452 Weeks
25mgUSD 7752 Weeks
50mgUSD 11502 Weeks
100mgUSD 18452 Weeks
Inquire bulk and customized quantity

Pricing updated 2021-01-23.Prices are subject to change without notice.

PD089828, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 406476Name: PD089828CAS#: 179343-17-0Chemical Formula: C18H18Cl2N6OExact Mass: 404.09191Molecular Weight: 405.28112Elemental Analysis: C, 53.34; H, 4.48; Cl, 17.50; N, 20.74; O, 3.95

Synonym:PD089828; PD089828; PD 089828.

IUPAC/Chemical Name:1-(2-amino-6-(2,6-dichlorophenyl)pyrido[2,3-d]pyrimidin-7-yl)-3-(tert-butyl)urea

InChi Key:RRWSNCZYJCOEFX-UHFFFAOYSA-N

InChi Code:InChI=1S/C18H18Cl2N6O/c1-18(2,3)26-17(27)25-15-10(13-11(19)5-4-6-12(13)20)7-9-8-22-16(21)24-14(9)23-15/h4-8H,1-3H3,(H4,21,22,23,24,25,26,27)

SMILES Code:O=C(NC(C)(C)C)NC1=NC2=NC(N)=NC=C2C=C1C3=C(Cl)C=CC=C3Cl

Technical Data

Appearance:
solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001

Additional Information

References

1: Hamby JM, Connolly CJ, Schroeder MC, Winters RT,Showalter HD, Panek RL, Major TC, Olsewski B, Ryan MJ, Dahring T, Lu GH, Keiser J, Amar A, Shen C,Kraker AJ, Slintak V, Nelson JM, Fry DW, Bradford L, Hallak H, Doherty AM. Structure-activity relationships for a novel series of pyrido[2,3-d]pyrimidine tyrosine kinase inhibitors. J Med Chem. 1997 Jul 18;40(15):2296-303.PubMed PMID: 9240345.

2: Dahring TK, Lu GH, Hamby JM, Batley BL, Kraker AJ, Panek RL.Inhibition of growth factor-mediated tyrosine phosphorylation in vascular smoothmuscle by PD 089828, a new synthetic protein tyrosine kinase inhibitor. J PharmacolExp Ther.1997 Jun;281(3):1446-56. PubMed PMID: 9190882.

品牌介绍
MedKoo 美帝药库公司以药物化学合成技术为核心,密切结合全球抗癌新药研发领域中的新技术、新理论、新趋势和新的发展方向,不断推出抗癌化合物新品种。 。 美帝药库MedKoo将在中国建立药物化学合成生产基地和多个现代化药物化合物存储仓库。 美帝药库的药物化合物来源于以下几个渠道:自主合成、委托化学合成、合作伙伴、和从国内外市场上选购。 MedKoo美帝药库的抗癌分子库 MedKoo的目标是打造全球规模最大、品种最多、类别最全和质量最好的小分子抗癌化合物库。MedKoo的抗癌药库将由下列5个分子库组成: (1)上市抗癌药库:该库将含有大约100个全球已批准上市的小分子抗癌化合物; (2)抗癌候选药物库:该分子库含有大约400个世界各国正在临床研究中抗癌小分子候选药物; (3)同系抗癌分子库:该分子库将含有多个化学结构类似或抗癌机制类似的分子包; (4)抗癌分子预制模块库:该库主要含有用于组建抗癌目标分子的分子模块包; (5)同位素标记抗癌分子库。